<DOC>
	<DOC>NCT01342146</DOC>
	<brief_summary>The purpose of the multicenter, randomized, open-label, controlled phase II study is to determine whether pegylated recombinant human growth hormone is effective in the treatment of children with growth hormone deficiency.</brief_summary>
	<brief_title>Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>have a height less than two standard deviations (SD) below the median height for individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak concentration &lt;7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in girls and ≤10 years in boys) at least 2 years less than his/her chronological age (CA); be in preadolescence (Tanner stage 1) and have a CA &gt;3 years; have a height value recorded 3 months before the start of GH treatment to calculate pretreatment GV; receive no prior GH treatment. sign informed consent patients with severe cardiopulmonary patients with hematological diseases a current or past history of malignant tumors immunodeficiency diseases mental diseases patients positive for hepatitis B eantibody (HBeAb) hepatitis B surface antigen (HBsAg) hepatitis B e antigen (HBeAg) patients with other growth disorders, such as Turner syndrome constitutional delay of growth and puberty, and Laron syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>pegylated Somatropin</keyword>
	<keyword>PEG-GH</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>PEG-rhGH</keyword>
	<keyword>Growth hormone deficiency (GHD)</keyword>
	<keyword>Phase 2 study</keyword>
</DOC>